Previous 10 | Next 10 |
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial ...
2023-10-23 08:21:00 ET Textainer Group Holdings ( TGH ) +43% . Mynaric ( MYNA ) +17% . Navios Maritime Holdings ( NM ) +17% to buy N Logistics in $2.28/share all-cash deal. Next. ( EGOX ) +16% . Harpoon Therapeutics ( HARP ) ...
2023-10-16 13:36:37 ET Gainers: Tempest Therapeutics ( TPST ) +98% . Momentus ( MNTS ) +51% . PCTEL ( PCTI ) +47% . Almacenes Exito ( EXTO ) +33% . Mereo Biopharma Group Plc ( MREO ) +30% . Rani Therapeutics Holdings ( RANI...
2023-10-16 12:17:55 ET DENVER, Colo., Oct. 16, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Processa Pharmaceuticals Inc (NASDAQ: PCSA), Mereo BioPharma Group PLC (NASDAQ: MREO), Tempest Therape...
2023-10-16 10:00:00 ET More on Health Care Select Sector SPDR Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further...
2023-10-16 09:56:56 ET DENVER, Colo., Oct. 16, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; LQR House Inc (NASDAQ: LQR), Better Therapeutics Inc (NASDAQ: BTTX), Mereo BioPharma Group PLC (NASDAQ: MREO)...
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET NOVATO, Cal...
NOVATO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI) will be presented at the American Society for Bone and Mineral Research 2023 ...
2023-09-21 18:10:58 ET Summary Mereo BioPharma's extended financial runway and reduced R&D spend improve its short-term risk profile. Diverse pipeline, led by setrusumab and alvelestat, offers long-term growth but awaiting key clinical readouts. The company's etigilimab co...
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate ...
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
Mereo BioPharma Group Website:
2024-06-20 09:00:06 ET Joseph Schwartz from Leerink Partners issued a price target of $8.00 for MREO on 2024-06-20 07:21:00. The adjusted price target was set to $8.00. At the time of the announcement, MREO was trading at $3.98. The overall price target consensus is at $...
2024-06-14 10:45:03 ET Cleanspark Inc (CLSK) CLSK is trading UP for the last 5 days, and it at trading at $18.30 with volume of 12,068,034 and a one day change of $0.33 (1.84%). Cleanspark Inc has a 52-week low of 3.38 and a 52-week high of $24.72. The business's 50-day moving avera...
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Dep...